Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miravitlles, M.
Right arrow Articles by Morell, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miravitlles, M.
Right arrow Articles by Morell, F.
(Chest. 1999;116:946-952.)
© 1999 American College of Chest Physicians

Specific Antibody Response Against the 23-Valent Pneumococcal Vaccine in Patients With {alpha}1-Antitrypsin Deficiency With and Without Bronchiectasis*

Marc Miravitlles, MD, PhD; Javier de Gracia, MD, PhD; María-José Rodrigo, MD, PhD; María-Jesús Cruz, MD; Montserrat Vendrell, MD; Rafael Vidal, MD, PhD and Ferran Morell, MD, PhD

* From the Department of Pneumology (Drs. Miravitlles, de Gracia, Vendrell, Vidal, and Morell) and the Department of Biochemistry (Drs. Rodrigo and Cruz), Immunology Unit, Hospital General Vall d'Hebron, Barcelona, Spain. Supported by Fondo de Investigaciones Sanitarias (FIS) grant 93/0482.

Correspondence to: Marc Miravitlles, MD, PhD, Rocafort 173–177, 3°1a, 08015 Barcelona, Spain; e-mail: marcm{at}hg.vhebron.es

Objective: To assess the specific antibody response against polyvalent pneumococcal vaccine in patients with {alpha}1-antitrypsin deficiency (AATD) and respiratory infections.

Design and participants: We investigated specific IgG, IgG1, and IgG2 antibody responses against the 23-valent antipneumococcal vaccine in 18 patients with AATD phenotype PiZZ, 9 of whom had bronchiectasis and 4 a history of recurrent pneumonia, and compared them with a control group of 40 healthy volunteers.

Interventions: Blood samples were drawn just prior to and 3 weeks after immunization.

Measurements and results: Quantification of specific IgG and its subclasses was performed by an enzyme-linked immunosorbent assay. For patients with AATD, mean increases in specific antipneumococcal titers were 4.7-fold (25 to 75% quartiles, 2.5- to 6.8-fold) for total IgG, 3.2-fold (1.2- to 4.9-fold) for IgG1, and 2.1-fold (1.8- to 3.7-fold) for IgG2. For the control group, the values were 3.3-fold (1.8- to 5.8-fold) for total IgG, 2.5-fold (1.9- to 3.4-fold) for IgG1, and 3.1-fold (1.9- to 4.5-fold) for IgG2; differences were not significant. Patients with bronchiectasis showed a tendency toward higher levels of IgG subclasses than both control subjects and patients without bronchiectasis; however, there was a tendency toward lower postvaccination serum levels of specific antipneumococcal IgG, IgG1, and IgG2 in patients with bronchiectasis compared with patients without bronchiectasis, but this trend did not reach statistical significance. Three of the four patients with recurrent pneumonia did not show an appropriate IgG2 response.

Conclusions: These results suggest that, as a group, patients with AATD have a preserved antibody response against pneumococcal polysaccharides. Patients with bronchiectasis show a tendency toward a decreased antibody response, even with increased serum levels of most Ig types. Individuals with an impaired IgG2 response seem to be at increased risk of recurrent pneumonia. Considering the pernicious effect of pulmonary infections on these patients and the preserved antibody response in a majority of them, pneumococcal vaccination should be recommended to patients with AATD.

Key Words: antibody response • {alpha}1-antitrypsin deficiency • bronchiectasis • IgG subclasses • pneumococcal vaccine




This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. Miravitlles, M. Vendrell, and J. de Gracia
Antibody deficiency in bronchiectasis
Eur. Respir. J., July 1, 2005; 26(1): 178 - 180.
[Full Text] [PDF]

Home page
 ChestHome page
M. Vendrell, J. de Gracia, M.-J. Rodrigo, M.-J. Cruz, A. Alvarez, M. Garcia, and M. Miravitlles
Antibody Production Deficiency With Normal IgG Levels in Bronchiectasis of Unknown Etiology
Chest, January 1, 2005; 127(1): 197 - 204.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Luisetti, M. Miravitlles, and R.A. Stockley
{alpha}1-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001
Eur. Respir. J., October 1, 2002; 20(4): 1050 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Miravitlles
Exacerbations of chronic obstructive pulmonary disease: when are bacteria important?
Eur. Respir. J., July 1, 2002; 20(36_suppl): 9S - 19s.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M.-J. RODRIGO, M. VENDRELL, M.-J. CRUZ, M. MIRAVITLLES, C. PASCUAL, F. MORELL, and J. DE GRACIA
Utility of the Antibody Response to a Conjugated Haemophilus influenzae Type B Vaccine for Diagnosis of Primary Humoral Immunodeficiency
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1462 - 1465.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American College of Chest Physicians.